September 5, 2012
The FDA has again delayed an approval decision for a new diarrhea drug from Salix Pharmaceuticals.
August 9, 2012
The Raleigh-based pharmaceutical firm licenses rights to an extended release version of the drug Rifaximin that targets gastrointestinal and respiratory ailments.
August 9, 2012
Four North Carolina-based life science firms report an overall mixed bag of results, but Raleigh-based Salix reports huge jump in sales.
Updated July 31, 2012
Salix will no longer add an additional 160 primary-care sales representatives later this year and plans to update its 2012 earnings forecast when it releases second-quarter results on Aug. 8.
July 30, 2012
Inside the Bulldog Blog: Quintiles lands drug promotion deal; Salix seeks FDA meeting about drug response; Furiex resubmits diabetes drug; Advanced Animal Diagnostics adds two execs.
May 8, 2012
Salix Pharmaceuticals announced on Monday a 62 percent increase in its first quarter revenue for 2012 with total product revenue at $171.1 million thanks in part to the company's leading drug Xifaxan.
May 1, 2012
Salix had been scheduled for a June 5 decision date on its experimental diarrhea treatment crofelemer. But the Raleigh company says FDA regulators need more time to review the submission.
April 26, 2012
An approval decision was expected on April 27. But the U.S. Food and Drug Administration has notified the Raleigh-based company that it needs more time. The new target date to issue an approval decision is July 27.
March 13, 2012
Salix says it will repurchase outstanding convertible senior notes that are due in 2028. The company also plans to repurchase up to $75 million of its outstanding common stock and will also use proceeds for corporate purposes.
February 28, 2012
After a 60 percent jump in revenue in 2011 to $540 million, the Raleigh-based drug firm forecasts a 36 percent jump in 2012 to $735 million.
February 22, 2012
Local tech briefs: Cary-based Visilink unveils LED-based wireless; Cary firm MercuryGate expands to Asia; Salix launches new drug trial; Furiex cuts its losses; iContact donates $200,000; Charlotte firm updates automation software.
Updated February 7, 2012
The Raleigh firm is tied up in a law suit over the development of the drug that's intended to help AIDS patients suffering with diarrhea.
December 21, 2011
Salix released successful phase 3 clinical trial results for the oral version of Relistor and now plans to submit a new drug application for the compound in the middle of 2012.
November 15, 2011
Salix is preparing for new set of Xifaxan phase 3 clinical trials studying the irritable bowel syndrome indication, which puts approval about two years away. But first the company will meet with an FDA advisory panel on Wednesday, eight months after receiving the complete response letter from the agency declining approval on Xifaxan as a new IBS treatment.
Updated November 15, 2011
Triangle-based Salix wants to expand use of its bowel drug but the FDA raised questions that concern an analyst who follows the company.
November 11, 2011
"Napo believes Salix has materially breached the collaboration agreement by unnecessarily stalling the advancement of this compound," Napo Pharmaceuticals says. "Most notably, Salix has failed to file an NDA one year after a highly successful phase 3 clinical trial or to prepare for commercial manufacture of the drug -- critical tasks that were fundamental to its responsibilities."
November 9, 2011
"The acquisition of Oceana expands our product portfolio of innovative products, furthers the diversification of Salix's base business and provides immediate added revenue," says Salix CEO Carolyn Logan.
August 31, 2011
Salix and drug partner Progenics Pharmaceuticals want to expand Relistor's use to treat opioid-induded constipation in patients taking the drugs for non-cancer pain.
August 9, 2011
Data from proposed irritable bowel syndrome drug Xifaxan faces further review, Salix says. The FDA rejected Xifaxan as IBS tgreatment in March.
May 9, 2011
The Raleigh-based company says that the suit's charges "are without merit."